Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by.
The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.” However, what exactly is being exchanged remains unknown; Kelun has more than a dozen oncology assets, with 11 in clinical trials and three in preclinical testing.
A Merck spokesperson said in an email the company had nothing to add beyond what was released in the disclosure.
Translated from Chinese, the disclosure says Merck will pay $17 million off the top and an additional $30 million after the agreement is formally signed. Kelun stands to earn up to $1.36 billion in cumulative milestones.
It’s not the first time Kelun has made a licensing splash. In 2018, it inked a deal for its midstage PD-L1 antibody with Harbour BioMed for up to $350 million.
As for Merck, the plucking of Kelun’s project comes as it reportedly considers larger M&A plays to capitalize on biotech’s bear market. A few of the names supposedly on the company’s shortlist are Mirati Therapeutics, Strand Therapeutics and Arcturus Therapeutics.
By Max Bayer
Source: fiercebiotech.com
Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med’s superstar status to reach new levels. The med is now the first weight loss treatment to score an FDA nod to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight.
Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an initial public offering (IPO) earlier in March, will have 40,453,467 new shares available. The offering also consists of 276,909 existing shares.
Taking over as CEO for an aging company in dire financial straits and in need of a slim-down was a challenging assignment for Christophe Bourdon. But under Bourdon’s watch, Leo Pharma is taking steps toward a rebound. Last month, the 115-year-old Danish private company reported that it cut its operating costs by 14% in 2023 while increasing its revenues by 7%.